2017
DOI: 10.1002/cbdv.201700117
|View full text |Cite
|
Sign up to set email alerts
|

Acetazolamide Inhibits the Level of Tyrosinase and Melanin: An Enzyme Kinetic, In Vitro, In Vivo, and In Silico Studies

Abstract: Melanin is the major factor that determines skin color and protects from ultraviolet radiation. In present study we evaluated the anti-melanogenesis effect of acetazolamide (ACZ) using four different approaches: enzyme kinetic, in vitro, in vivo and in silico. ACZ demonstrated significant inhibitory activity (IC 7.895 ± 0.24 μm) against tyrosinase as compared to the standard drug kojic acid (IC 16.84 ± 0.64 μm) and kinetic analyses showed that ACZ is a non-competitive inhibitor without cytotoxic effect. In in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
10

Relationship

4
6

Authors

Journals

citations
Cited by 27 publications
(13 citation statements)
references
References 38 publications
0
13
0
Order By: Relevance
“…A series of experiments were performed to determine the inhibition kinetics of 3d by following the already reported method. [ ] The inhibitor concentrations for 3d were 0.00, 0.019, and 0.038 μM. Substrate L‐DOPA concentration was between 0.125 and 2 mM in all kinetic studies.…”
Section: Methodsmentioning
confidence: 99%
“…A series of experiments were performed to determine the inhibition kinetics of 3d by following the already reported method. [ ] The inhibitor concentrations for 3d were 0.00, 0.019, and 0.038 μM. Substrate L‐DOPA concentration was between 0.125 and 2 mM in all kinetic studies.…”
Section: Methodsmentioning
confidence: 99%
“…The potency of ACE against tyrosinase was investigated by exactly following our published method in various articles [19][20][21]. In the first step, 20 nM of phosphate buffer at pH 6.8 was prepared, and 140 µL of the solution was transferred in each well of the assay plate.…”
Section: Mushroom Tyrosinase Inhibition Assaymentioning
confidence: 99%
“…Melanoma only represents a small subset of these tumors, yet it is the most common skin tumor type, with increasing incidence and mortality rates worldwide ( 1 , 2 ). Currently, the primary treatments of malignant melanoma are surgical excision, immunotherapy, adjuvant chemotherapy, targeted therapy drugs ( 3 ) and radiotherapies ( 2 , 4 ). However, these therapeutic strategies do not facilitate the current clinical practice requirements due to the high metastatic potential and drug resistance ( 5 , 6 ).…”
Section: Introductionmentioning
confidence: 99%